These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. Dybal EJ; Haas GP; Maughan RL; Sud S; Pontes JE; Hillman GG J Urol; 1992 Oct; 148(4):1331-7. PubMed ID: 1404669 [TBL] [Abstract][Full Text] [Related]
9. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Salup RR; Wiltrout RH Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432 [TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model. Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455 [TBL] [Abstract][Full Text] [Related]
15. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727 [TBL] [Abstract][Full Text] [Related]
16. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Huland E; Heinzer H; Huland H Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219 [TBL] [Abstract][Full Text] [Related]
17. Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model. Hillman GG; Maughan RL; Grignon DJ; Yudelev M; Rubio J; Tekyi-Mensah S; Layer A; Che M; Forman JD Clin Cancer Res; 2001 Jan; 7(1):136-44. PubMed ID: 11205901 [TBL] [Abstract][Full Text] [Related]
18. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Yockman JW; Kim WJ; Chang CW; Kim SW Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245 [TBL] [Abstract][Full Text] [Related]
19. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703 [TBL] [Abstract][Full Text] [Related]